$VIRX
Viracta Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024539 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.871M $10.94M $3.711M
YoY Change 21.32% 194.77% 59.96%
% of Gross Profit
Research & Development $6.703M $7.139M $7.088M
YoY Change -8.22% 0.72% 128.28%
% of Gross Profit
Depreciation & Amortization $57.00K $45.00K $52.00K
YoY Change -3.39% -13.46%
% of Gross Profit
Operating Expenses $11.57M $18.08M $14.80M
YoY Change 2.26% 22.16% 270.72%
Operating Profit -$18.08M -$14.80M
YoY Change 22.16% 270.72%
Interest Expense $450.0K $139.0K $125.0K
YoY Change -448.84% 11.2% 89.39%
% of Operating Profit
Other Income/Expense, Net $798.0K $0.00 $0.00
YoY Change -100.0%
Pretax Income -$10.33M -$17.74M -$14.91M
YoY Change -9.79% 18.97% 221.42%
Income Tax
% Of Pretax Income
Net Earnings -$10.33M -$17.74M -$14.91M
YoY Change -9.79% 18.97% 265.63%
Net Earnings / Revenue
Basic Earnings Per Share -$0.47 -$0.40
Diluted Earnings Per Share -$0.27 -$470.6K -$399.3K
COMMON SHARES
Basic Shares Outstanding 38.20M 37.71M 37.23M
Diluted Shares Outstanding 37.71M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $91.04M $77.07M $111.0M
YoY Change -12.08% -30.56% 326.86%
Cash & Equivalents $36.77M $23.47M $111.0M
Short-Term Investments $54.27M $53.60M
Other Short-Term Assets $2.704M $2.613M $2.032M
YoY Change 57.3% 28.59% 27.0%
Inventory
Prepaid Expenses $2.704M
Receivables
Other Receivables
Total Short-Term Assets $93.75M $79.68M $113.0M
YoY Change -10.95% -29.5% 309.12%
LONG-TERM ASSETS
Property, Plant & Equipment $148.0K $184.0K $258.0K
YoY Change -38.84% -28.68% -35.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.830M $1.972M $2.538M
YoY Change -23.65% -22.3%
Total Long-Term Assets $2.244M $2.518M $3.525M
YoY Change -31.56% -28.57% 761.86%
TOTAL ASSETS
Total Short-Term Assets $93.75M $79.68M $113.0M
Total Long-Term Assets $2.244M $2.518M $3.525M
Total Assets $95.99M $82.20M $116.5M
YoY Change -11.57% -29.47% 315.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.540M $1.616M $2.098M
YoY Change -12.44% -22.97% 1298.67%
Accrued Expenses $7.193M $7.393M $4.693M
YoY Change 23.97% 57.53% 38.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $10.01M $9.387M $7.161M
YoY Change 10.2% 31.09% 100.76%
LONG-TERM LIABILITIES
Long-Term Debt $24.88M $4.869M $5.026M
YoY Change 416.23% -3.12%
Other Long-Term Liabilities $0.00 $130.0K $378.0K
YoY Change -100.0% -65.61%
Total Long-Term Liabilities $24.88M $4.869M $5.026M
YoY Change 416.23% -3.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.01M $9.387M $7.161M
Total Long-Term Liabilities $24.88M $4.869M $5.026M
Total Liabilities $34.89M $14.26M $12.19M
YoY Change 150.94% 16.98% 241.66%
SHAREHOLDERS EQUITY
Retained Earnings -$214.9M -$204.5M -$154.2M
YoY Change 29.71% 32.62% -77.96%
Common Stock $4.000K $4.000K $4.000K
YoY Change 0.0% 0.0% 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $61.10M $67.81M $104.0M
YoY Change
Total Liabilities & Shareholders Equity $95.99M $82.20M $116.5M
YoY Change -11.57% -29.47% 315.72%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$10.33M -$17.74M -$14.91M
YoY Change -9.79% 18.97% 265.63%
Depreciation, Depletion And Amortization $57.00K $45.00K $52.00K
YoY Change -3.39% -13.46%
Cash From Operating Activities -$7.903M -$7.157M -$7.598M
YoY Change 9.6% -5.8% 79.2%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$1.000K -$228.0K
YoY Change -100.0% -99.56%
Acquisitions
YoY Change
Other Investing Activities -$203.0K -$52.06M -$4.000M
YoY Change 1201.4%
Cash From Investing Activities -$203.0K -$52.06M -$4.228M
YoY Change 968.42% 1131.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.41M 1.103M 88.00K
YoY Change -10857.29% 1153.41% -98.77%
NET CHANGE
Cash From Operating Activities -7.903M -7.157M -7.598M
Cash From Investing Activities -203.0K -52.06M -4.228M
Cash From Financing Activities 21.41M 1.103M 88.00K
Net Change In Cash 13.30M -58.11M -11.74M
YoY Change -279.04% 395.07% -504.76%
FREE CASH FLOW
Cash From Operating Activities -$7.903M -$7.157M -$7.598M
Capital Expenditures $0.00 -$1.000K -$228.0K
Free Cash Flow -$7.903M -$7.156M -$7.370M
YoY Change 9.89% -2.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92007
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3295878
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Address Line1
EntityAddressAddressLine1
2533 S. Coast Hwy. 101, Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Cardiff
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001061027
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-51531
dei Entity Registrant Name
EntityRegistrantName
VIRACTA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
400-8470
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
VIRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38197345
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23472000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103554000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
53595000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2613000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1719000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
79680000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
105273000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
184000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
242000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
362000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
640000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1972000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2397000
CY2022Q3 us-gaap Assets
Assets
82198000
CY2021Q4 us-gaap Assets
Assets
108552000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1616000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2901000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7393000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5802000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
378000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
381000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9387000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9084000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4869000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4819000
CY2022Q3 us-gaap Other Long Term Debt
OtherLongTermDebt
130000
CY2021Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
0
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
278000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10248
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10248
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10248
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10248
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
5452000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
5452000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37902849
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37902849
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37424863
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37424863
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
267103000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
254592000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-199000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-204548000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165677000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
67812000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
94371000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82198000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108552000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7139000
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7088000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
19559000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
16558000
CY2022Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
4000000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
88478000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10939000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3711000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19456000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11422000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
18078000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
14799000
us-gaap Operating Expenses
OperatingExpenses
39015000
us-gaap Operating Expenses
OperatingExpenses
116458000
CY2022Q3 virx Gain Loss On Royalty Purchase Agreement Non Operating
GainLossOnRoyaltyPurchaseAgreementNonOperating
0
CY2021Q3 virx Gain Loss On Royalty Purchase Agreement Non Operating
GainLossOnRoyaltyPurchaseAgreementNonOperating
0
virx Gain Loss On Royalty Purchase Agreement Non Operating
GainLossOnRoyaltyPurchaseAgreementNonOperating
0
virx Gain Loss On Royalty Purchase Agreement Non Operating
GainLossOnRoyaltyPurchaseAgreementNonOperating
13500000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18078000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14799000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39015000
us-gaap Operating Income Loss
OperatingIncomeLoss
-102958000
CY2022Q3 virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
0
CY2021Q3 virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
0
virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
0
virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
257000
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
474000
CY2021Q3 us-gaap Interest Income Other
InterestIncomeOther
10000
us-gaap Interest Income Other
InterestIncomeOther
534000
us-gaap Interest Income Other
InterestIncomeOther
28000
CY2022Q3 us-gaap Interest Expense
InterestExpense
139000
CY2021Q3 us-gaap Interest Expense
InterestExpense
125000
us-gaap Interest Expense
InterestExpense
390000
us-gaap Interest Expense
InterestExpense
352000
CY2022Q3 us-gaap Other Expenses
OtherExpenses
0
CY2021Q3 us-gaap Other Expenses
OtherExpenses
0
us-gaap Other Expenses
OtherExpenses
0
us-gaap Other Expenses
OtherExpenses
290000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
335000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-115000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
144000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-357000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-17743000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14914000
us-gaap Net Income Loss
NetIncomeLoss
-38871000
us-gaap Net Income Loss
NetIncomeLoss
-103315000
CY2022Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-199000
CY2021Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-199000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17942000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14914000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39070000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-103315000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.44
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37705517
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37353418
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37614166
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29995784
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
94371000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2022Q1 virx Vestingofearlyexerciseofstockoption
Vestingofearlyexerciseofstockoption
1000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1772000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-10546000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
85605000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1956000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10582000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
77003000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
70000
CY2022Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1034000
CY2022Q3 virx Vestingofearlyexerciseofstockoption
Vestingofearlyexerciseofstockoption
1000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7646000
CY2022Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-199000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-17743000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
67812000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-46200000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81000
CY2021Q1 virx Vestingofearlyexerciseofstockoption
Vestingofearlyexerciseofstockoption
1000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
62317000
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
97982000
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
83302000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
396000
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
5452000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
644000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-79231000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
124744000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
136000
CY2021Q2 virx Vestingofearlyexerciseofstockoption
Vestingofearlyexerciseofstockoption
1000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1386000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-9170000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
117097000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
87000
CY2021Q3 virx Vestingofearlyexerciseofstockoption
Vestingofearlyexerciseofstockoption
1000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1704000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14914000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
103975000
us-gaap Net Income Loss
NetIncomeLoss
-38871000
us-gaap Net Income Loss
NetIncomeLoss
-103315000
virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
0
virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
257000
virx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0
virx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
84478000
virx Purchased In Process Research And Development
PurchasedInProcessResearchAndDevelopment
0
virx Purchased In Process Research And Development
PurchasedInProcessResearchAndDevelopment
4000000
us-gaap Share Based Compensation
ShareBasedCompensation
11374000
us-gaap Share Based Compensation
ShareBasedCompensation
3734000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
153000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
119000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
175000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
virx Change In Fair Value Of Preferred Stock Warrant Liability
ChangeInFairValueOfPreferredStockWarrantLiability
0
virx Change In Fair Value Of Preferred Stock Warrant Liability
ChangeInFairValueOfPreferredStockWarrantLiability
290000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
894000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1359000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-425000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-743000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1285000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
118000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1592000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-203000
virx Increase Decrease In Lease Liabilities1
IncreaseDecreaseInLeaseLiabilities1
-3000
virx Increase Decrease In Lease Liabilities1
IncreaseDecreaseInLeaseLiabilities1
12000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
130000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27554000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11640000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
233000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
4000000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
54418000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
800000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
17143000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-53663000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12910000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1034000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62320000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
101000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
304000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1135000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62624000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-80082000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
63894000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103554000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47089000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23472000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110983000
us-gaap Interest Paid Net
InterestPaidNet
332000
us-gaap Interest Paid Net
InterestPaidNet
257000
virx Warrant Liability Reclassification To Equity
WarrantLiabilityReclassificationToEquity
0
virx Warrant Liability Reclassification To Equity
WarrantLiabilityReclassificationToEquity
396000
virx Issuance Of Convertible Preferred Stock Noncash Transaction Upon Merger
IssuanceOfConvertiblePreferredStockNoncashTransactionUponMerger
0
virx Issuance Of Convertible Preferred Stock Noncash Transaction Upon Merger
IssuanceOfConvertiblePreferredStockNoncashTransactionUponMerger
5452000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
83302000
virx Issuance Of Common Stock Noncash Transaction Upon Merger
IssuanceOfCommonStockNoncashTransactionUponMerger
0
virx Issuance Of Common Stock Noncash Transaction Upon Merger
IssuanceOfCommonStockNoncashTransactionUponMerger
97982000
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1119
CY2022Q3 virx Percentage Of Outstanding Common Stock Of Combined Company
PercentageOfOutstandingCommonStockOfCombinedCompany
0.86
CY2021Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
65000000.0
CY2021Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
3.5-for-one
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-204500000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
77100000
CY2022Q3 virx Working Capital
WorkingCapital
70300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates.</span></p>
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
0
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
199000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1695000
CY2022Q3 virx Accrued Clinical Trial And Contract Expenses
AccruedClinicalTrialAndContractExpenses
3879000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents and short-term investments.</span></p>
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
75358000
us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
75159000
CY2022Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
100000
CY2021Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
0
us-gaap Debt Securities Available For Sale Accrued Interest Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
0
us-gaap Debt Securities Available For Sale Accrued Interest Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
0
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8118991
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5177848
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2635000
CY2021Q4 virx Accrued Clinical Trial And Contract Expenses
AccruedClinicalTrialAndContractExpenses
3380000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
204000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
180000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
675000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
547000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7393000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5802000
us-gaap Costs And Expenses
CostsAndExpenses
800000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
700000
CY2022Q3 us-gaap Other Long Term Debt
OtherLongTermDebt
100000
CY2021Q4 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
45000000.0
us-gaap Line Of Credit Facility Borrowing Capacity Description
LineOfCreditFacilityBorrowingCapacityDescription
The second tranche of $20.0 million is available upon request by the Company and Lenders approval until December 30, 2022, and the third tranche, $25.0 million, is available at the Company's request subject Lenders' discretion. As of September 30, 2022, neither tranche had been requested.
CY2022Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.1040
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1714000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1714000
CY2022Q3 virx Long Term Debt Maturities Repayments Of Principal After Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearThree
1572000
CY2022Q3 virx Aggregate Minimum Payments Under Debt Arrangements
AggregateMinimumPaymentsUnderDebtArrangements
5000000
CY2022Q3 virx Unamortized Discount Of Future Minimum Payments Under Long Term Debt Arrangement
UnamortizedDiscountOfFutureMinimumPaymentsUnderLongTermDebtArrangement
131000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4869000
CY2021Q1 us-gaap Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Combination1
BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1
103400000
CY2021Q1 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
1600000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
18956000
CY2021Q1 virx Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Acquired Ipr And D Projects
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredIprAndDProjects
84478000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
103434000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
17143000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
395000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
3768000
CY2021Q1 virx Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Accrued Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities
1955000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
18956000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37902849
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37424863
CY2022Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
18811552
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10248
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9837739
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6429819
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7646000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1704000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11374000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3734000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3964000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.33
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
3697000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.85
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
83000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.22
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.22
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7183000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.67
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
745000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.22
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P3Y4M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
149000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
4.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
64000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
4.22
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
532000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y8M12D
CY2022Q2 virx Fair Value Of Shares Issuable Under Employee Stock Purchase Plan
FairValueOfSharesIssuableUnderEmployeeStockPurchasePlan
25000
CY2020Q2 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
option for an additional year
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
0.4
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
600000
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y

Files In Submission

Name View Source Status
0000950170-22-024539-index-headers.html Edgar Link pending
0000950170-22-024539-index.html Edgar Link pending
0000950170-22-024539.txt Edgar Link pending
0000950170-22-024539-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
virx-20220930.htm Edgar Link pending
virx-20220930.xsd Edgar Link pending
virx-ex10_1.htm Edgar Link pending
virx-ex31_1.htm Edgar Link pending
virx-ex31_2.htm Edgar Link pending
virx-ex32_1.htm Edgar Link pending
virx-ex32_2.htm Edgar Link pending
virx-20220930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
virx-20220930_cal.xml Edgar Link unprocessable
virx-20220930_pre.xml Edgar Link unprocessable
virx-20220930_def.xml Edgar Link unprocessable
virx-20220930_lab.xml Edgar Link unprocessable